BSX Boston Scientific Corporation Total Debt to Capital

The Boston Scientific (BSX) total debt-to-equity ratio chart demonstrates prudent asset management and a transparent development strategy. Meanwhile, 0.55 captures a new level as the company implements the high-margin Farapulse pulsed field ablation system. Successes in electrophysiology, strategic acquisitions, and a recovery in demand for elective surgeries are driving the share price growth.

Selecting stocks with a high margin of safety begins with an analysis of the debt load. This indicator compares total liabilities to equity, determining the business's degree of dependence on borrowed funds. For Boston Scientific (BSX), moderate leverage is critically important when scaling the Farapulse system and expanding into urology. An optimal debt balance ensures financial stability during periods of rate volatility. The history of the total debt-to-equity ratio clearly demonstrates this dynamic.